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Background: Pharmacological doses of corticoids may result in adrenal suppression but with individual sensitivity.
In paediatric inflammatory bowel disease (IBD), glucocorticoids are needed in the majority of the patients but there
are less studies related to tapering off the drugs. The objective of this study was to estimate the frequency of
adrenal insufficiency in children with IBD that were at the end of their systemic glucocorticoid therapy course.
Methods: The study was a retrospective case series of 59 consecutive paediatric IBD patients (median age 14.1 years;
Crohn’s disease n = 22, ulcerative colitis n = 26, unclassified colitis n = 11) that were on oral prednisolone therapy about
to be discontinued. The study patients were treated in a tertiary university hospital setting. Serum morning cortisol
was measured with Immulite 2000 cortisol kit. Values < 20 nmol/l are undetectable and indicate adrenal suppression,
values > 69 nmol/l are considered to represent normal basal secretion.
Results: The morning cortisol was below the reference range in 20% of the patients and undetectable in 10%. Low
cortisol levels associated with higher daily glucocorticoid doses (median 7.2 mg/m2 vs. 3.0 mg/m2 in patients with
normal cortisol levels, p < 0.05) and with the long duration of the treatment (median 11 months vs. 4 months,
p < 0.05). Patients with undetectable cortisol levels recovered within few weeks (median 5.6 weeks).
Conclusions: In paediatric IBD prolonged courses of glucocorticoids are frequent due to the steroid-dependent
nature of the disease in a considerable proportion of patients. Adrenal suppression may occur in at least one fifth
of the patients despite slowly tapering off the glucocorticoids. Notably, this is based on a set of serum cortisol
measurements by request of experienced clinicians. All paediatric IBD patients receiving conventional doses of
oral glucocorticoids should be subjected to screening for adrenal suppression when anticipated discontinuation
of the drug.
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Inflammatory bowel disease (IBD) encompassing ulcera-
tive colitis (UC), Crohn’s disease (CD) and unclassified
colitis (IBDU) is a chronic, disabling disease of the gastro-
intestinal tract. Similarly to adult patients, the number of
children suffering from IBD has risen during the past de-
cades and in Western countries its incidence is growing
with an alarming pace [1-4]. The reason for this increase
is at present unknown.
Glucocorticoids represent the backbone of treatment
of active IBD [5-7]. In paediatric patients the therapy is* Correspondence: kaija-leena.kolho@helsinki.fi
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article, unless otherwise stated.commenced with 1-2 mg/kg/day of prednisone equiva-
lents (max 60 mg) and tapered off preferably during
10 weeks [6]. However, glucocorticoid dependency affects
approximately 20-40% of the patients and prolonged ster-
oid courses are often seen in clinical practice [8,9].
Long-term supraphysiological dosing of systemic glu-
cocorticoids produces side effects that vary in presentation
from patient to patient. Adrenal suppression is a condition
in which adrenal glands do not produce adequate amounts
of cortisol in response to physiological stress. It is caused
by the suppression of the hypothalamic-pituitary-adrenal
(HPA) axis by the circulating exogenous glucocorticoids
and may lead into adrenal crisis or even death [10].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Table 1 The clinical characteristics of the 59 paediatric
patients with inflammatory bowel disease (IBD)
Diagnosis CD/IBDU/UC* 22/11/26
Male/female 29/30
Age at the time of the study (median, range) 14 yrs (2.6–18)
Prednisolone daily dose
10 mg 21
5 mg 18
5 mg on alternate days 20
Length of the prednisolone therapy
(months; median, range)
5 (0.5–39)
Maintenance medication**
5-ASA 27
5-ASA and/or Aza 19
TNF-α-antagonist 11
No medication 2
The first morning cortisol level was analyzed during weaning or at the end of
oral prednisolone therapy. *CD: Crohn’s disease; IBDU: unclassified colitis;
UC: ulcerative colitis. **5-ASA: 5-acetosalicylic acid; Aza: azathioprine.
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ommended as a useful first step to screen cases of sus-
pected adrenal insufficiency [11]. If the levels are low or
undetectable, the patient most likely suffers from adrenal
suppression. However, if the first morning cortisol levels
are normal, the patient may still have a blunted HPA
axis response to stress. Then the ACTH stimulation test
should follow in order to confirm the responsiveness of
the HPA axis [12].
Risk factors for the development of adrenal suppres-
sion are not yet fully understood. However, high gluco-
corticoid dose and long duration of the therapy seem to
associate with the increased risk [10] but intestinal ab-
sorption and genetic factors related to glucocorticoid
sensitivity are likely to play an additional role [13]. In-
deed, it is recommended that all children who have re-
ceived pharmacologic doses of systemic glucocorticoid
therapy for more than two weeks should be assessed for
adrenal insufficiency [14]. Paediatric patients with active
IBD on oral glucocorticoid therapy fulfil the at-risk cri-
teria, however in many of them the condition goes un-
noticed [12]. Adrenal suppression is an understudied
and possibly an under-recognized complication of ex-
tended steroid use in paediatric IBD patients with poten-
tially lethal consequences. We therefore aimed to assess
the frequency of adrenal insufficiency in children with
IBD receiving systemic glucocorticoids.
Methods
The study group consisted of paediatric IBD patients
that were treated in the Outpatient Clinic of the Chil-
dren’s Hospital in Helsinki University Central Hospital, a
tertiary care center, between January 2008 and July 2011.
All diagnoses were based on modern endoscopic criteria
including upper gastrointestinal endoscopy and imaging
of the small bowel when there is a suspicion of Crohn’s
disease [15]. The majority of our patients with CD and
UC need glucocorticoids, the proportion of such patients
being stable regardless of the year of diagnosis [16]. Ex-
perienced gastroenterologists instructed the tapering of
glucocorticoids according to disease activity along the
lines suggested in the recent paediatric guidelines of UC
[17]. The data was collected retrospectively. The inclu-
sion criteria were 1) IBD diagnosis [15] and 2) serum
cortisol measured when oral predisolone was about to
be discontinued. The serum cortisol was measured by
request of clinicians. Altogether, 59 patients were identi-
fied. The clinical characteristics of the patients are pre-
sented in Table 1. Steroid therapy related side effects
(cushingoid rounding of the cheeks, weight gain, acne,
mood changes) were carefully registered. Serum cortisol
was measured routinely with Immulite 2000 cortisol kit
(Diagnostic Products Corporation, LA, CA) in samples
scheduled at 9 AM [18]. The daily prednisolone dosewas withheld until after the measurement. The detection
limit of the assay is 20 nmol/l, intra-assay coefficient of
variation of <7.4% and inter-assay coefficient of variation
of < 9.55%. The reference range for normal serum morn-
ing cortisol defined by the clinical laboratory is 69-
632 nmol/l for children aged 2-13 years, 69-789 nmol/l
for children aged 14-15 years and 150-650 nmol/l for pa-
tients older than 16 years.
P < 0.05 was set for statistical significance. Mann-
Whitney U-test, Kruskal-Wallis test and Spearman’s
rank order correlation tests were used when appropriate.
Values are expressed as median, range.
All patients were participants of our ongoing study on
paediatric IBD approved by the ethics committee of the
Children’s Hospital, University of Helsinki. The study
was conducted in accordance with the ethical standards
of the responsible committee on human experimentation
and with the Helsinki Declaration of 1975, as revised in
1983. Unfortunately, the total number of paediatric IBD
patients treated with glucocorticoids at our clinic during
the study period was not registered.
Results
At the end of the systemic prednisolone therapy when ta-
pering off was considered, the median dose of prednisolone
was 5 mg (<5 mg – 10 mg; median duration of the therapy
4.7 months; 0.5 – 39 months), Table 1. The median serum
morning cortisol level was 204 nmol/l (<20-437 nmol/l) be-
ing below the reference range in 12/59 (20%) of the patients
and undetectable (<20 nmol/l) in 6/12 patients (2/6 with
CD; cortisol levels measured at 9.30 at latest). The children
in whom the serum cortisol level was low received higher
daily doses of prednisolone than patients that had normal
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3.0 mg/m2, 1.3-10 mg/m2, p < 0.05), Figure 1. In addition,
the length of the steroid therapy was longer in the patients
that had low cortisol levels (11 months, 3-39 months vs.
4 months, 0.5-33 months, p < 0.05). The dose of steroid was
unaltered at minimum during the preceding week of cortisol
measurement. Also previous steroid therapy affected the
cortisol levels, patients that had received glucocorticoids be-
fore had lower cortisol levels than patients that were on
their first steroid course (174 nmol/l, <20-319 nmol/l, n = 25
vs. 225 nmol/l, <20-437 nmol/l, n = 34, p < 0.05).
Disease subtype or medication was not associated with
the morning cortisol levels (data not shown). Gender did
not relate to the cortisol levels, however age correlated
strongly (r = 0.421, p < 0.05), younger children having
lower levels. The appearance of visible steroid therapy
related side effects was not associated with the serum
cortisol values. The time of measurement (median
8:39 AM, 6:20 – 10:42 AM) did not differ between the
groups with normal vs. abnormal cortisol values (P = NS,
data not shown). Reassuringly, patients with undetect-
able cortisol levels recovered within few weeks (5.6 weeks)
when on hydrocortisone substitution or on low dose
prednisolone/budesonide (and on alternate days on hydro-
cortisone). The cortisol measurements during recovery
phase, however, occurred at 2 to 4- week intervals as
scheduled by the clinicians. ACTH-stimulation tests areFigure 1 Serum morning cortisol levels in paediatric IBD
patients at the end of oral prednisolone therapy. The 59 patients
are divided into groups according to their present glucocorticoid dose.
Bars represent the range of the cortisol level; horizontal lines the median
cortisol level. The percentages above the bars describe how many percent
of the patients had normal serum cortisol level. The horizontal dashed line
at 69 nmol/l is the lower limit for normal serum morning cortisol level. In
the first group receiving * <5 mg defines group of patients receiving 5 mg
prednisolone on alternate days N= 20, in the second group receiving
5 mg a day N= 18, and in the third group receiving 10 mg a day N= 21.not routinely conducted at our clinic when discontinuing
glucocorticoids in patients with IBD. The test was
performed only in five of the study patients showing
normal stimulatory response in all of them (data not
shown).
Discussion
In this pilot study we assessed serum morning cortisol
levels in children with IBD at the end of systemic gluco-
corticoid (prednisolone) therapy. We found that in 20%
of the patients the morning cortisol measurement was
below the reference range and low cortisol values associ-
ated with higher daily glucocorticoid doses and longer
duration of the therapy.
Systemic glucocorticoid therapy is a well known cause
of secondary adrenal insufficiency. In IBD, 40 to 80 per-
cent of the patients may receive steroid therapy at some
point during the disease course (with a starting dose of
1-2 mg/kg), and several patients need prolonged courses
because of steroid-dependent disease [8,16,19]. However,
studies concerning HPA axis function in paediatric IBD
patients are few. Escher et al found that children who
received 10-20 mg of prednisone for active IBD had a
mean morning plasma cortisol of 98 nmol/l [20]. When
the dose was reduced to 2.5 – 10 mg that corresponds
with the steroid doses used in our study, the mean
serum morning cortisol level was similar to our results.
However, they did not report how many patients failed
their cutoff of 150 nmol/l for normal serum morning
cortisol. In a study on adult IBD patients, the serum
morning cortisol levels corresponded with our findings
and also the number (29%) that had abnormal serum
morning cortisol was roughly similar to ours [21].
Long duration of glucocorticoid therapy and high ster-
oid doses are risk factors for the development adrenal
insufficiency [10,14]. Consistently, in our study higher
glucocorticoid doses and prolonged duration of the ther-
apy associated with low serum morning cortisol levels.
Patients were also more likely to have low serum morn-
ing cortisol levels if they had received previous steroid
treatment. This is in concordance with a study on adult
IBD patients, where a past history of glucocorticoid
treatment was predictive of abnormal adrenal stimula-
tion test [12]. Of notice, very low levels were occasion-
ally detected after few months of therapy.
Limitation of our study was that we did not use any
provocative testing for the assessment of the HPA axis
as the study design was retrospective. However, studies
have shown that serum morning cortisol levels under
approximately 100 nmol/l are suggestive of adrenal in-
sufficiency [11,22]. Our routine cutoff of 69 nmol/l by
clinical laboratory was even stricter. Hypocortisolaemia
at this level can represent only the tip of the iceberg of
the HPA axis dysfunction. Patients that have serum
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normal circumstances might still have an inadequate ad-
renal response to stress [12]. Therefore it is more than
likely that our results underestimate the prevalence of
adrenal insufficiency and that some degree of HPA axis
suppression is present in more than 20% percent of
paediatric IBD patients at the end of systemic gluco-
corticoid course. The cortisol levels, however, were mea-
sured by request of clinicians and not on all patients
treated with glucocorticoids during this time period.
Potential confounding factors that could affect the
serum morning cortisol measurement are the cross-
reactivity of the steroid preparations with cortisol assays,
timing of the blood sample, compliance to the pre-
scribed medication and possible stress factors that could
elevate the serum cortisol levels, such as infections.
Most of the common glucocorticoid drugs cross-react
with cortisol assays. Therefore, our patients were advised
not to take their daily steroid dose on the sample day
and the sample was scheduled to be withdrawn at 9:00,
approximately 24 hours after the last steroid dose. At
that point, no excess glucocorticoid activity (i.e. drug in-
duced activity) from the ingested medication can be mea-
sured from the sample and this approach was also
recommended in the international guidelines [17,23]. The
compliance of the patients to the medication is a frequent
matter of debate. Most of the paediatric IBD patients,
however, seem to adhere well to the medication as demon-
strated in our study on measured glucocorticoid bioactiv-
ity in serum [23]. In addition, none of the patients
presented with fever and/or symptoms of infection likely
to cause a stress response.
Conclusions
In conclusion, this study shows that at least every fifth
paediatric IBD patient presents with abnormal or even un-
detectable serum cortisol values at the end of systemic
glucocorticoid treatment. Without screening, however in
many patients the condition goes unnoticed. For the pa-
tients with low levels of cortisol, hydrocortisone substitution
was introduced until observing cortisol values within normal
range. This practice reduces the risk of serious consequences
of adrenal insufficiency [14] and most likely improves the
wellbeing of the patients. We recommend screening for ad-
renal insufficiency in children with IBD when the daily dose
is low and/or the therapy is about to be discontinued to de-
pict patients in need of hydrocortisone substitution.
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